QQ客服 官方微博 反馈留言

	Phase 1 trial of JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies.
	Yang, Jianliang; Yang, Sheng; Song, Haifeng; Han, Xiaohong; Han, Ying; Jiang, Shiyu; Yao, Jiarui; Zhang, Zhishang; Zhang, Shuxiang; Liu, Peng
	2018
卷号	36期号:15
ISSN号	0732-183X
DOI	10.1200/JCO.2018.36.15_suppl.e15108
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6351392
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Yang, Jianliang,Yang, Sheng,Song, Haifeng,et al. Phase 1 trial of JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies.[J],2018,36(15).
APA	Yang, Jianliang.,Yang, Sheng.,Song, Haifeng.,Han, Xiaohong.,Han, Ying.,...&Shi, Yuankai.(2018).Phase 1 trial of JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies..,36(15).
MLA	Yang, Jianliang,et al."Phase 1 trial of JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies.".36.15(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。